Corrigendum to "Mycoplasma pneumoniae vaccine protective efficacy and adverse reactions-Systematic review and meta-analysis" [Vaccine 27 (2009) 2347-2446] (DOI:10.1016/j.vaccine.2009.01.135);Mycoplasma pneumoniae vaccine protective efficacy and adverse reactions-Systematic review and meta-analysis

Vaccine

Volumn 27, Issue 18, 2009, Pages 2437-2446

  Linchevski, Inbal ^a   Klmenet, Eyal ^a   Nir Paz, Ran ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Meta analysis; Mycoplasma pneumoniae; Vaccine

Indexed keywords

BACTERIAL VACCINE; INACTIVATED VACCINE; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG FEVER; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MALAISE; META ANALYSIS; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SKIN INDURATION; SYSTEMATIC REVIEW;

EID: 62749205742     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.003     Document Type: Erratum

References (59)

1. Waites K.B., and Talkington D.F. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 17 October (4) (2004) 697-728 [table of contents]
2. Principi N., Esposito S., Blasi F., and Allegra L. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections. Clin Infect Dis 32 May 1 (9) (2001) 1281-1289
3. Esposito S., Cavagna R., Bosis S., Droghetti R., Faelli N., and Principi N. Emerging role of Mycoplasma pneumoniae in children with acute pharyngitis. Eur J Clin Microbiol Infect Dis 21 August (8) (2002) 607-610
4. Foy H.M. Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. Clin Infect Dis 17 August (Suppl. 1) (1993) S37-S46
5. Marston B.J., Plouffe J.F., File Jr. T.M., Hackman B.A., Salstrom S.J., Lipman H.B., et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 157 August 11-25 (15) (1997) 1709-1718
6. File T.M. Community-acquired pneumonia. Lancet 362 December 13 (9400) (2003) 1991-2001
7. Don M., Fasoli L., Paldanius M., Vainionpaa R., Kleemola M., Raty R., et al. Aetiology of community-acquired pneumonia: serological results of a paediatric survey. Scand J Infect Dis 37 11-12 (2005) 806-812
8. Porath A., Schlaeffer F., and Lieberman D. The epidemiology of community-acquired pneumonia among hospitalized adults. J Infect 34 January (1) (1997) 41-48
9. Lauderdale T.L., Chang F.Y., Ben R.J., Yin H.C., Ni Y.H., Tsai J.W., et al. Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. Respir Med 99 September (9) (2005) 1079-1086
10. Klement E., Talkington D.F., Wasserzug O., Kayouf R., Davidovitch N., Dumke R., et al. Identification of risk factors for infection in an outbreak of Mycoplasma pneumoniae respiratory tract disease. Clin Infect Dis 43 November 15 (10) (2006) 1239-1245
11. Mogabgab W.J. Mycoplasma pneumoniae and adenovirus respiratory illnesses in military and university personnel, 1959-1966. Am Rev Respir Dis 97 March (3) (1968) 345-358
12. Kashiwagi S., Hayashi J., Nomura H., Kajiyama W., Ikematsu H., Shingu T., et al. An outbreak of Mycoplasma pneumoniae infections in a hospital in Japan. Kurume Med J 32 4 (1985) 293-296
13. Kleemola M., and Jokinen C. Outbreak of Mycoplasma pneumoniae infection among hospital personnel studied by a nucleic acid hybridization test. J Hosp Infect 21 July (3) (1992) 213-221
14. Dorigo-Zetsma J.W., de Wit M., Szabo J.S., and Schneeberger P.M. Epidemic of respiratory tract infections by Mycoplasma pneumoniae in an institute for mentally disabled, investigated with polymerase chain reaction of a throat swab specimen. Ned Tijdschr Geneeskd 143 Jun 12 (24) (1999) 1261-1265
15. Klausner J.D., Passaro D., Rosenberg J., Thacker W.L., Talkington D.F., Werner S.B., et al. Enhanced control of an outbreak of Mycoplasma pneumoniae pneumonia with azithromycin prophylaxis. J Infect Dis 177 January (1) (1998) 161-166
16. Leibowitz Z., Schvartzman P., Epstein L., Lis I., and Naot Y. An outbreak of Mycoplasma pneumoniae pneumonia in two kibbutzim: a clinical and epidemiologic study. Isr J Med Sci 24 February (2) (1988) 88-92
17. Muldoon R.L., Raucci J., Kowalski J., and Rajashekaraiah K. An outbreak of mycoplasma pneumoniae respiratory illness in a semi-closed religious commune. Ann Emerg Med 11 Novemvber (11) (1982) 613-615
18. Waring A.L., Halse T.A., Csiza C.K., Carlyn C.J., Arruda Musser K., and Limberger R.J. Development of a genomics-based PCR assay for detection of Mycoplasma pneumoniae in a large outbreak in New York State. J Clin Microbiol 39 April (4) (2001) 1385-1390
19. Adamo M.A., and Deshaies E.M. Emergency decompressive craniectomy for fulminating infectious encephalitis. J Neurosurg 108 January (1) (2008) 174-176
20. Walter N.D., Grant G.B., Bandy U., Alexander N.E., Winchell J.M., Jordan H.T., et al. Community outbreak of Mycoplasma pneumoniae infection: school-based cluster of neurologic disease associated with household transmission of respiratory illness. J Infect Dis 198 November 1 (9) (2008) 1365-1374
21. Top Jr. F.H. Control of adenovirus acute respiratory disease in U.S. Army trainees. Yale J Biol Med 48 July (3) (1975) 185-195
22. Maniloff J. Mycoplasmas: molecular biology and pathogenesis (1992), American Society for Microbiology, Washington, DC
23. Egger M., Davey Smith G., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 315 September 13 (7109) (1997) 629-634
24. Mogabgab W.J. Protective efficacy of killed Mycoplasma pneumoniae vaccine measured in large-scale studies in a military population. Am Rev Respir Dis 108 October (4) (1973) 899-908
25. Wenzel R.P., Craven R.B., Davies J.A., Hendley J.O., Hamory B.H., and Gwaltney Jr. J.M. Field trial of an inactivated Mycoplasma pneumoniae vaccine. I. Vaccine efficacy. J Infect Dis 134 December (6) (1976) 571-576
26. Wenzel R.P., Craven R.B., Davies J.A., Hendley J.O., Hamory B.H., and Gwaltney Jr. J.M. Protective efficacy of an inactivated Mycoplasma pneumoniae vaccine. J Infect Dis 136 August (Suppl.) (1977) S204-S207
27. Mogabgab W.J. Acute respiratory illnesses in university (1962-1966), military and industrial (1962-1963) populations. Am Rev Respir Dis 98 September (3) (1968) 359-379
28. Mogabgab W.J., Marchand S., Mills G., and Beville R. Efficacy of inactivated Mycoplasma pneumoniae vaccine in man. Dev Biol Stand 28 (1975) 597-608
29. Mogabgab W.J. Efficacy of inactivated Mycoplasma pneumoniae vaccine demonstrated by protection in large field trials. Ann N Y Acad Sci 225 (1973) 453-461
30. Smith C.B., Friedewald W.T., and Chanock R.M. Inactivated Mycoplasma pneumoniae vaccine. Evaluation in volunteers. J Am Med Assoc 199 February 6 (6) (1967) 353-358
31. Smith C.B., Chanock R.M., Friedewald W.T., and Alford R.H. Mycoplasma pneumoniae infections in volunteers. Ann N Y Acad Sci 143 July 28 (1) (1967) 471-483
32. Weibel R.E., Stokes Jr. J., Leagus M.B., Mascoli C.C., and Hilleman M.R. Respiratory virus vaccines. V. Field evaluation for efficacy of heptavalent vaccine. Am Rev Respir Dis 94 September (3) (1966) 362-379
33. Weibel R.E., Stokes Jr. J., Leagus M.B., Mascoli C.C., Tytell A.A., Woodhour A.F., et al. Respiratory virus vaccines. VII. Field evaluation of respiratory syncytial, parainfluenza 1, 2, 3, and Mycoplasma pneumoniae vaccines, 1965-1966. Am Rev Respir Dis 96 October (4) (1967) 724-739
34. Fernald G.W., and Glezen W.P. Humoral and cellular immune responses to an inactivated Mycoplasma pneumoniae vaccine in children. J Infect Dis 127 May (5) (1973) 498-504
35. Jensen K.E., Senterfit L.B., Chanock R.M., Smith C.B., and Purcell R.H. An inactivated mycoplasma pneumoniae vaccine. J Am Med Assoc 194 October 18 (3) (1965) 248-252
36. Metzgar D.P., Woodhour A.F., Vella P.P., Weibel R.E., Stokes Jr. J., Drake M.E., et al. Respiratory virus vaccines. II. Mycoplasma pneumoniae (Eaton agent) vaccines. Am Rev Respir Dis 94 July (1) (1966) 1-9
37. Sweet B.H., Tytell A.A., Potash L., Weibel R.E., Stokes Jr. J., Drake M.E., et al. Respiratory virus vaccines. 3. Pentavalent respiratory syncytial-parainfluenza-mycoplasma pneumoniae vaccine. Am Rev Respir Dis 94 September (3) (1966) 340-349
38. Woodhour A.F., Sweet B.H., Tytell A.A., Potash L., Stokes Jr. J., Weibel R.E., et al. Respiratory virus vaccines. IV. Heptavalent respiratory syncytial-parainfluenza-mycoplasma-influenza vaccine in institutionalized persons. Am Rev Respir Dis 94 September (3) (1966) 350-361
39. Somerson N.L., Senterfit L.B., and Hamparian V.V. Development of Mycoplasma pneumoniae vaccine. Ann N Y Acad Sci 225 (1973) 425-435
40. Brown R.C., Hendley J.O., and Gwaltney Jr. J.M. Mycoplasma pneumoniae vaccine: antigenicity of buffered antigens in volunteers. Infect Immun 5 May (5) (1972) 657-661
41. Leagus M.B., Weibel R.E., Mascoli C.C., Stokes Jr. J., and Hilleman M.R. Respiratory virus vaccines. VI. Serologic responses to heptavalent vaccine among young children in families. Am Rev Respir Dis 95 May (5) (1967) 838-844
42. Greenberg H., Helms C.M., Brunner H., and Chanock R.M. Asymptomatic infection of adult volunteers with a temperature sensitive mutant of Mycoplasma pneumoniae. Proc Natl Acad Sci U S A 71 October (10) (1974) 4015-4019
43. Brunner H., Greenberg H., James W.J., Horswood R.L., and Chanock R.M. Decreased virulence and protective effect of genetically stable temperature-sensitive mutants of Mycoplasma pneumoniae. Ann N Y Acad Sci 225 (1973) 436-452
44. Smorodintsev A.A., and Kolesnikov L.V. Associated live vaccine against influenza, adenovirus type 4 and Mycoplasma pneumoniae. Trudy Inst Im Pastera 58 (1982) 3-13
45. Kolesnikov L.V., Shamanova M.G., Grodinskaia A.E., Evdokimov N.M., and Khlopova I.N. Immunogenic and reactogenic properties of Mycoplasma pneumoniae at different attenuation levels. Vestn Akad Med Nauk SSSR 25 8 (1970) 41-45
46. Chanock R.M., Smith C.B., Friedewald W.T., Gutekunst R., Steinberg P., Fuld S., et al. Prospects for live and inactivated vaccines. Proceedings of the first international conference on vaccines against viral and rickettsial diseases of man. Pan American Health Organization Scientific publication no. 147 (1967) 132-140
47. Mogabgab W.J. Field evaluation of killed mycoplasma pneumoniae vaccine. Proceedings of the first international conference on vaccines against viral and rickettsial diseases of man. Pan American Health Organization Scientific publication no. 147 (1967) 125-131
48. Mogabgab W.J. Mycoplasma pneumoniae vaccines. Proceedings of the international conference on vaccines against viral and rickettsial diseases of man. Pan American Health Organization Scientific publication no. 226 (1971) 117-126
49. Mogabgab W.J. Mycoplasma pneumoniae infections in university and military personnel and effectiveness of vaccination. J Lab Clin Med 66 (1965) 1003
50. Hilleman MR, Weibel RE, Woodhour AF, Stokes J, Jr., Mascoli CC, Leagus MB, et al. Development and field evaluation of combined polyvalent respiratory virus vaccines. Proceedings of the first international conference on vaccines against viral and rickettsial diseases of man. Pan American Health Organization Scientific publication no. 147. 1967. p. 141-54.
51. Domenech C., Leveque N., Lina B., Najioullah F., and Floret D. Role of Mycoplasma pneumoniae in pediatric encephalitis. Eur J Clin Microbiol Infect Dis 28 January (1) (2009) 91-94
52. Dumke R., Catrein I., Herrmann R., and Jacobs E. Preference, adaptation and survival of Mycoplasma pneumoniae subtypes in an animal model. Int J Med Microbiol 294 September (2-3) (2004) 149-155
53. Jacobs E., Vonski M., Oberle K., Opitz O., and Pietsch K. Are outbreaks and sporadic respiratory infections by Mycoplasma pneumoniae due to two distinct subtypes?. Eur J Clin Microbiol Infect Dis 15 January (1) (1996) 38-44
54. Gray G.C., Schultz R.G., Gackstetter G.D., McKeehan J.A., Aldridge K.V., Hudspeth M.K., et al. Prospective study of respiratory infections at the U.S. Naval Academy. Mil Med 166 September (9) (2001) 759-763
55. Lodes M.J., Suciu D., Wilmoth J.L., Ross M., Munro S., Dix K., et al. Identification of upper respiratory tract pathogens using electrochemical detection on an oligonucleotide microarray. PLoS ONE 2 9 (2007) e924
56. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol Cell Biol 82 October (5) (2004) 497-505
57. Nir-Paz R., Michael-Gayego A., Ron M., and Block C. Evaluation of eight commercial tests for Mycoplasma pneumoniae antibodies in the absence of acute infection. Clin Microbiol Infect 12 July (7) (2006) 685-688
58. Fernald G.W., and Clyde W.A. Protective effect of vaccines in experimental Mycoplasma pneumoniae disease. Infect Immun 1 June (6) (1970) 559-565
59. Nicholas R.A., Ayling R.D., and McAuliffe L. Vaccines for mycoplasma diseases in animals and man. J Comp Pathol 140 Feb-Apr (2-3) (2009) 85-96